Significant differences exist when analyzing cancer management approaches in the America and the Continent. The American model, generally characterized by for-profit insurance and a emphasis on innovation, often leads to early adoption of novel therapies, albeit at a significantly greater cost. Conversely, Continental systems frequently rely on gov